In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MannKind closes $81.4mm IPO

Executive Summary

After filing for an $86.25mm initial public offering in April, MannKind (drug delivery and cancer therapeutics) revised the offering in early July to sell 5.5mm common shares between $13-15 each, to bring in up to $82.5mm. It finally completed the IPO in late July, selling 6.25mm common shares priced at $14 each, netting the company $81.4mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies